Literature DB >> 26611206

Characterization of apela, a novel endogenous ligand of apelin receptor, in the adult heart.

Ábel Perjés1,2, Teemu Kilpiö1, Johanna Ulvila1, Johanna Magga1, Tarja Alakoski1, Zoltán Szabó1, Laura Vainio1, Eveliina Halmetoja1, Olli Vuolteenaho3, Ulla Petäjä-Repo4,5, István Szokodi2,6, Risto Kerkelä7,8.   

Abstract

The G protein-coupled apelin receptor regulates important processes of the cardiovascular homeostasis, including cardiac development, cardiac contractility, and vascular tone. Most recently, a novel endogenous peptide ligand for the apelin receptor was identified in zebrafish, and it was named apela/elabela/toddler. The peptide was originally considered as an exclusively embryonic regulator, and so far its function in the adult organism remains elusive. We show here that apela is predominantly expressed in the non-cardiomyocyte fraction in the adult rodent heart. We also provide evidence that apela binds to apelin receptors in the heart. Using isolated adult rat hearts, we demonstrate, that just like the fellow receptor agonist apelin, apela increases cardiac contractility and induces coronary vasodilation already in the nanomolar level. The inotropic effect, as revealed by Western blot analysis, is accompanied by a significant increase in extracellular signal-regulated kinase (ERK) 1/2 phosphorylation. Pharmacological inhibition of ERK1/2 activation markedly attenuates the apela-induced inotropy. Analysis of samples from infarcted mouse hearts showed that expression of both apela and apelin receptor is induced in failing mouse hearts and correlate with left ventricular ejection fraction. Hence, we conclude that apela is present in the adult heart, is upregulated in post-infarction cardiac remodeling, and increases cardiac contractility in an ERK1/2-dependent manner.

Entities:  

Keywords:  Apela; Cardiovascular; Cell signaling; Contractility; Extracellular signal-regulated kinase (ERK); G protein-coupled receptor (GPCR); Heart failure; Myocardial infarction; Peptides

Mesh:

Substances:

Year:  2015        PMID: 26611206     DOI: 10.1007/s00395-015-0521-6

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  27 in total

1.  Is ELABELA a reliable biomarker for hypertensive disorders of pregnancy?

Authors:  Rong Huang; Jing Zhu; Lin Zhang; Xiaolin Hua; Weiping Ye; Chang Chen; Kun Sun; Weiye Wang; Liping Feng; Jun Zhang
Journal:  Pregnancy Hypertens       Date:  2019-06-27       Impact factor: 2.899

Review 2.  Vascular effects of apelin: Mechanisms and therapeutic potential.

Authors:  Amreen Mughal; Stephen T O'Rourke
Journal:  Pharmacol Ther       Date:  2018-05-25       Impact factor: 12.310

3.  Elabela as a novel marker: Well-correlated with WIfI amputation risk score in lower extremity arterial disease patients.

Authors:  Mehmet Kaplan; Fethi Yavuz; Gizem Ilgın Kaplan; Nurbanu Bursa; Ertan Vuruşkan; Murat Sucu
Journal:  Anatol J Cardiol       Date:  2021-05       Impact factor: 1.596

Review 4.  Apelinergic System Structure and Function.

Authors:  Kyungsoo Shin; Calem Kenward; Jan K Rainey
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

5.  Serum Elabela level is significantly increased in patients with acromegaly.

Authors:  Hilmi Erdem Sumbul; Erdinc Gulumsek; Begum Seyda Avci; Nurettin Ay; Ramazan Azim Okyay; Ahmet Riza Sahin; Jeffrey Gold; Akkan Avci; Mevlut Koc
Journal:  Ir J Med Sci       Date:  2022-06-04       Impact factor: 1.568

6.  ELABELA plasma concentrations are increased in women with late-onset preeclampsia.

Authors:  Bogdan Panaitescu; Roberto Romero; Nardhy Gomez-Lopez; Percy Pacora; Offer Erez; Felipe Vadillo-Ortega; Lami Yeo; Sonia S Hassan; Chaur-Dong Hsu
Journal:  J Matern Fetal Neonatal Med       Date:  2018-07-22

Review 7.  The biological function of ELABELA and APJ signaling in the cardiovascular system and pre-eclampsia.

Authors:  Yuanyuan Liu; Liquan Wang; Hongjun Shi
Journal:  Hypertens Res       Date:  2019-01-09       Impact factor: 3.872

Review 8.  International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.

Authors:  Cai Read; Duuamene Nyimanu; Thomas L Williams; David J Huggins; Petra Sulentic; Robyn G C Macrae; Peiran Yang; Robert C Glen; Janet J Maguire; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

9.  Sarcolipin haploinsufficiency prevents dystrophic cardiomyopathy in mdx mice.

Authors:  Satvik Mareedu; Ronald Pachon; Jayapalraj Thilagavathi; Nadezhda Fefelova; Rekha Balakrishnan; Nandita Niranjan; Lai-Hua Xie; Gopal J Babu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-11-20       Impact factor: 4.733

10.  The network map of Elabela signaling pathway in physiological and pathological conditions.

Authors:  Shobha Dagamajalu; D A B Rex; G P Suchitha; Akhila B Rai; Jan K Rainey; T S Keshava Prasad
Journal:  J Cell Commun Signal       Date:  2021-08-02       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.